AI Article Synopsis

  • Conversion disorder causes psychological stress to manifest physically; this study compared haloperidol and midazolam in treating this condition.
  • The clinical trial involved 140 patients, with results showing that haloperidol had a higher success rate (91.5%) compared to midazolam (64.3%), although haloperidol also led to more side effects shortly after treatment.
  • Overall, haloperidol was more effective with similar recovery times for both medications, indicating it may be the preferable option despite its minor side effects.

Article Abstract

Introduction: Conversion disorder is a condition in which the patient shows psychological stress in physical ways. This study aimed to compare the effects of haloperidol versus midazolam in patients with conversion disorder.

Methods: This double-blind randomized clinical trial was conducted on patients with conversion disorder who had presented to the emergency department, throughout 2015. Patients were randomly divided into two groups and were either treated with 2.5 mg of intravenous (IV) haloperidol or 2.5 mg of IV midazolam. Recovery rate, time to recovery, and side effects of both drugs 1 hour, 24 hours, and 1 week after treatment were compared using SPSS19.

Results: 140 patients were divided into two groups of 70. There were no significant differences between the groups regarding the baseline characteristics. 12 (17.1%) patients who were treated with IV haloperidol experienced drug side effects within 1 hour and 12 (17.1%) within 24 hours, while only 3 (4.3%) patients in IV midazolam experienced side-effects within 1 hour after drug administration (p = 0.026). The symptoms of the disease subsided in 45 (success rate: 64.3%) patients in midazolam and in 64 (success rate: 91.5%) participants in haloperidol group (P<0.001). Mean recovery time was 31.24 ± 7.03 minutes in IV midazolam and 30.53 ± 7.11 minutes in IV haloperidol group (p = 0.592). Absolute risk reduction (ARR) of treating patients with haloperidol compared to midazolam is about 27%.

Conclusion: The response of patients to treatment with haloperidol is clearly better than midazolam. Although more transient and minor side-effects were observed in the group treated with haloperidol compared to midazolam group, serious side-effects were rare for both treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289157PMC

Publication Analysis

Top Keywords

conversion disorder
12
intravenous haloperidol
8
haloperidol versus
8
versus midazolam
8
randomized clinical
8
clinical trial
8
patients conversion
8
divided groups
8
side effects
8
patients midazolam
8

Similar Publications

Prion Protein Endoproteolysis: Cleavage Sites, Mechanisms and Connections to Prion Disease.

J Neurochem

January 2025

Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Canada.

Highly abundant in neurons, the cellular prion protein (PrP) is an obligatory precursor to the disease-associated misfolded isoform denoted PrP that accumulates in the rare neurodegenerative disorders referred to either as transmissible spongiform encephalopathies (TSEs) or as prion diseases. The ability of PrP to serve as a substrate for this template-mediated conversion process depends on several criteria but importantly includes the presence or absence of certain endoproteolytic events performed at the cell surface or in acidic endolysosomal compartments. The major endoproteolytic events affecting PrP are referred to as α- and β-cleavages, and in this review we outline the sites within PrP at which the cleavages occur, the mechanisms potentially responsible and their relevance to pathology.

View Article and Find Full Text PDF

Interorgan lipid transport is crucial for organism development and the maintenance of physiological function. Here, we demonstrate that long-chain acyl-CoA synthetase (dAcsl), which catalyzes the conversion of fatty acids into acyl-coenzyme As (acyl-CoAs), plays a critical role in regulating systemic lipid homeostasis. dAcsl deficiency in the fat body led to the ectopic accumulation of neutral lipids in the gut, along with significantly reduced lipoprotein contents in both the fat body and hemolymph.

View Article and Find Full Text PDF

Research progress in diagnosis and treatment of psychogenic pseudosyncope in children.

Cardiol Young

January 2025

Department of Pediatric Cardiovasology, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Psychogenic pseudosyncope is one of the primary causes of transient loss of consciousness in children and adolescents, essentially classified as a conversion disorder that significantly impacts patients' quality of life. Clinically, psychogenic pseudosyncope shares certain similarities with vasovagal syncope in terms of pre-syncope symptoms and triggers, making it sometimes difficult to differentiate and easily misdiagnosed. Therefore, placing emphasis upon the characteristics of psychogenic pseudosyncope is crucial for early identification and treatment, which holds significant importance for the mental and psychological health of children and adolescents.

View Article and Find Full Text PDF

Ultrahigh-Power Carbon-Based Supercapacitors through Order-Disorder Balance.

Small

January 2025

Institute of Smart City and Intelligent Transportation, Southwest Jiaotong University, Chengdu, 610031, China.

Although carbon-based supercapacitors (SCs) hold the advantages of high-power and large-current characteristics, they are difficult to realize ultrahigh-power density (> 200 kW kg) and maintain almost constant energy density at ultrahigh power. This limitation is mainly due to the difficulty in balancing the structural order related to the electrical conductivity of carbon materials and the structural disorder related to the pore structure. Herein, we design a novel super-structured tubular carbon (SSTC) with a crosslinked porous conductive network to solve the structure order-disorder tradeoff effect in carbon materials.

View Article and Find Full Text PDF

The controlled growth of two-dimensional (2D) perovskite atop three-dimensional (3D) perovskite films reduces interfacial recombination and impedes ion migration, thus improving the performance and stability of perovskite solar cells (PSCs). Unfortunately, the random orientation of the spontaneously formed 2D phase atop the pre-deposited 3D perovskite film can deteriorate charge extraction owing to energetic disorder, limiting the maximum attainable efficiency and long-term stability of the PSCs. Here, we introduce a meta-amidinopyridine ligand and the solvent post-dripping step to generate a highly ordered 2D perovskite phase on the surface of a 3D perovskite film.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!